Macrolides as immunomodulatory medications for the therapy of chronic lung diseases.
about
Secretion properties, clearance, and therapy in airway diseaseMacrolides for diffuse panbronchiolitisMacrolides for diffuse panbronchiolitisMacrolides for diffuse panbronchiolitisMacrolides for diffuse panbronchiolitisInternational Consensus Document (ICON): Common Variable Immunodeficiency DisordersHow I treat common variable immune deficiency.Evaluation and management of pulmonary disease in ataxia-telangiectasiaMacrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilmRevealing the dynamics of polymicrobial infections: implications for antibiotic therapy.Azithromycin concentrations in blood and gingival crevicular fluid after systemic administration.Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onsetThe role of Gr-1(+) cells and tumour necrosis factor-α signalling during Clostridium difficile colitis in mice.Do genetic susceptibility, Toll-like receptors, and pathogen-associated molecular patterns modulate the effects of wear?Macrolide antibiotics and survival in patients with acute lung injury.Macrolides in chronic inflammatory skin disorders.Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination.N-alpha-PGP and PGP, potential biomarkers and therapeutic targets for COPDSensorineural hearing loss in patients with cystic fibrosis.New macrolide, lincosaminide and streptogramin B antibiotics.Antibiotic therapy for exacerbations of chronic obstructive pulmonary disease (COPD).How to set up a severe asthma service.Azithromycin in periodontal treatment: more than an antibiotic.Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.Untangling asthma phenotypes and endotypes.Managing older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnostic and therapeutic challenges.A review on guidelines for management and treatment of common variable immunodeficiency.Updates in the management of stable chronic obstructive pulmonary disease.The role of macrolides in noncystic fibrosis bronchiectasisImmunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler.Chronic lung disease in common variable immune deficiency (CVID): A pathophysiological role for microbial and non-B cell immune factors.Clarithromycin suppresses human respiratory syncytial virus infection-induced Streptococcus pneumoniae adhesion and cytokine production in a pulmonary epithelial cell line.Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection.Effect of Clarithromycin on the Expression of UL16-Binding Protein 2 in Human Cells.Clarithromycin inhibits interleukin-13-induced goblet cell hyperplasia in human airway cells.Combination of erythromycin and dexamethasone improves corticosteroid sensitivity induced by CSE through inhibiting PI3K-δ/Akt pathway and increasing GR expression.Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study.Are the antimicrobial properties of macrolides required for their therapeutic efficacy in chronic neutrophilic airway diseases?Anti-inflammatory effects of tilmicosin in a noninfectious mouse model of allergic asthma.
P2860
Q21195704-083EBF14-1EEF-40C8-9940-193EB36654D8Q24186520-DF629E66-2869-45B0-A2E7-3F8AE2075BBCQ24200544-2CDC6538-F6F7-4C9D-A1DC-C297844D587EQ24235571-C55C1A9F-874C-44A8-8C59-3E44F39263EFQ24240570-2B9C9DF3-8ACF-4A70-BD94-92951488526DQ26777304-AA1E9882-C7B1-4545-8ACA-3F978D4A1955Q33997226-1FF67F3B-D7DB-4013-BC0D-D90FD1F422C2Q34120793-853DCE68-FC90-41A6-A198-652A400542E5Q34408724-A8D3888E-E840-41F6-AC5A-C2BEC1E11536Q34554419-80B2AA3D-304F-460D-8741-EF85B41176D1Q35078545-3DB25651-4C51-4CF4-B987-6B378DA01B09Q35143420-06BB79AF-9CE2-4C28-B287-D0F5EBE831BDQ35423526-30E70A99-99A6-4974-B5C0-FF6A72E9CB88Q35425921-29DD1C18-0B47-4D16-BAC1-0CEF7208C0CCQ35929943-4BE93D0C-410E-4BA4-AF6A-FC728723E119Q35997016-898F6C8F-4FB1-4640-8620-69EB1D6ACE4FQ37080915-4DE83EEC-6BC4-4955-B17E-48BEA6A95A01Q37220006-B382F80C-869A-48C6-9C0B-F59FF423447CQ37533266-36AFD2FA-57B7-4156-9A6D-390ACD214317Q37774378-D5B42042-7A41-43E4-8EED-831993D56241Q37814698-619EEB0E-67CE-4358-9D9D-56514F7366CCQ37892643-5497F423-1B0E-47B5-923E-F8AE4A1BE45BQ37952308-47E0C14B-F337-4075-ACF8-5F830429E2B2Q37959271-03D855F4-8073-4779-9390-8A24E804C3A9Q38010795-2B93AF0D-E6A9-4590-9339-C636B4EDA084Q38066413-C0240FDC-93CB-46D0-90AA-2A7D9FC75BB5Q38111423-583812B3-BD99-43B0-A3BA-4CE026A2E82DQ38578596-CC9F9230-E452-4A04-80C1-34D0C72B9CDBQ38833477-81D46E3B-92B1-4746-B085-D40FDC3B3617Q38925706-6788CFEC-4D87-488C-95B6-1730373BF834Q39077092-493BE500-BBBE-40AA-86AF-6EF35AE8EF05Q39320060-4BE19B66-365A-45E3-809B-9A799930CDB3Q39860101-50E3FC34-ECE8-4164-A25D-2EF8A524E72AQ40719253-23BD93AB-1606-4F8C-B481-A4287396E292Q44966446-82596BFC-9683-4976-8FF5-313D83DD5756Q48189418-129D95C9-E677-4BA6-A06C-9AE69EC90BF8Q49049243-86FCB4F0-2CFA-4666-9F57-5C34C2DAB3BBQ49147142-DCA872E1-2B40-4499-B3CE-336E738335F8Q50279663-FD54707A-D2BA-4261-B1EA-428F941CC97B
P2860
Macrolides as immunomodulatory medications for the therapy of chronic lung diseases.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Macrolides as immunomodulatory medications for the therapy of chronic lung diseases.
@ast
Macrolides as immunomodulatory medications for the therapy of chronic lung diseases.
@en
type
label
Macrolides as immunomodulatory medications for the therapy of chronic lung diseases.
@ast
Macrolides as immunomodulatory medications for the therapy of chronic lung diseases.
@en
prefLabel
Macrolides as immunomodulatory medications for the therapy of chronic lung diseases.
@ast
Macrolides as immunomodulatory medications for the therapy of chronic lung diseases.
@en
P1476
Macrolides as immunomodulatory medications for the therapy of chronic lung diseases.
@en
P2093
Bruce K Rubin
Yolanda S López-Boado
P304
P356
10.1016/J.COPH.2008.01.010
P577
2008-03-12T00:00:00Z